Intellia Therapeutics, Inc.

US$11.35As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:NTLAHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR (1.92%)
Div yield —
ROE (55.44%)
Biotechnology
Beta (5Y) 1.82
PE TTM —
TSR TTM (10.06%)
Mkt cap US$1.590B
ROIC (32.95%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$11
(3.81%)
(79.15%)
Hold 8|5|1|0|3
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.19
0.21
0.22
0.23
19.60%
22.64%
14.71%
17.30%
Revenue$M
75.88
73.65
77.04
81.33
2.93%
(0.31%)
5.53%
6.51%
Peers (US$1.590B)
Cap (US$)
PE
1.603B
65.92x
Capital
TTM
5Y
10Y
Leveragex
0.091
0.267
0.256
EBIT/Intx
0.999
0.429
0.386
Own earn%
91.42
29.13
29.57
Sh yield%
16.67
19.09
28.32
Owners
Insiders/Inst%
12.73
23.37
Short interest%
1.68
SBC / revenue%
5.13
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
23
Op margin range%
9–13
$1 testx
—
Incr. ROIC%
0